Get the Stockscreener App
1.385
8.88%
-0.135
After Hours:
1.38
-0.005
-0.36%
Tiziana Life Sciences Ltd Stock (TLSA) Latest News
Tiziana Life Sciences CEO to present at 37th Annual ROTH Conference - Proactive Investors UK
Tiziana Life Sciences to Present at the 37th Annual Roth Conference - The Manila Times
Tiziana Life Sciences Reveals Growth Strategy at Major ROTH ConferenceKey Updates Expected - StockTitan
Tiziana Life Sciences Regains Compliance with Nasdaq Listing Minimum Bid Price Rule - The Manila Times
Tiziana Life Sciences Regains Compliance with Nasdaq Listing Requirements - Nasdaq
Tiziana Life Sciences Dodges Delisting: How Company Saved Its Nasdaq Status - StockTitan
Oramed Pharmaceuticals And 2 Other Penny Stocks With Promising Potential - Simply Wall St
Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer's Disease - Informazione.it
Can Tiziana's Foralumab Enable Breakthroughs In Neuroinflammatory And Neurodegenerative Diseases? - RTTNews
Tiziana Life Sciences stock soars to 52-week high of $1.75 - Investing.com
Democrat-led states join legal fight over Trump's mass firings of federal workers -March 06, 2025 at 10:38 pm EST - Marketscreener.com
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) Stock Hits Multi-Month High After Filing a Key IND with the FDA - DRP Journal
Tiziana: Foralumab Drug Development Presses On With Additional EAP Enrollment - Seeking Alpha
Sector Update: Health Care -March 04, 2025 at 03:39 pm EST - Marketscreener.com
Tiziana submits FDA investigational new drug application - Proactive Investors UK
Tiziana Life Sciences Files New Drug Application for ALS Drug Candidate -March 04, 2025 at 09:03 am EST - Marketscreener.com
Tiziana Life Sciences Advances ALS Treatment with FDA IND Submission - TipRanks
Tiziana Life Sciences Files Investigational New Drug Application With FDA For ALS Phase 2 Clinical Trial - Marketscreener.com
Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial - The Manila Times
Could This Intranasal Therapy Change ALS Treatment? Tiziana Seeks FDA Approval - StockTitan
Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Significant Drop in Short Interest - Defense World
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week - MSN
Why Tiziana Life Sciences Ltd (TLSA) is Skyrocketing So Far in 2025 - Insider Monkey
Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
Tiziana Life Sciences' lead candidate demonstrates favorable safety profile and clinical response - Proactive Investors UK
Market movers: Ideal Power, Tiziana Life Sciences, Medicus Pharma... - Proactive Investors
Tiziana Life Sciences nasal anti-CD3 therapy shows promise in treating traumatic brain injury, study reveals - Proactive Investors UK
Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive Results for Nasal Anti-CD3 Therapy in Traumatic Brain Injury - The Manila Times
Can Tiziana's Nasal Therapy Revolutionize Traumatic Brain Injury Treatment? New Study Says Yes - StockTitan
Tiziana Life Sciences Announces Groundbreaking Study Published in Nature Neuroscience Demonstrating Positive… - Informazione.it
Tiziana Life Sciences nearing completion of long COVID study on foralumab - Proactive Investors Australia
Small cap headlines: Candel Therapeutics, Sintana Energy, Trust Stamp, Tiziana Life Sciences... - Proactive Investors UK
Tiziana Life Sciences Announces Long Covid Study to Complete in Second Quarter - The Manila Times
Can This Nasal Therapy Solve Long COVID? Tiziana's Breakthrough Approach Targets Brain Inflammation - StockTitan
Stoke Therapeutics (NASDAQ:STOK) and Tiziana Life Sciences (NASDAQ:TLSA) Head to Head Survey - Defense World
Tiziana Life Sciences Announces Agreement With Renaissance Lakewood -February 21, 2025 at 10:50 am EST - Marketscreener.com
Tiziana Life Sciences & Renaissance Partner on Nasal Foralumab Production - Contract Pharma
Tiziana Life Sciences Teams Up With Renaissance Lakewood on Nasal Drug Delivery - Marketscreener.com
Tiziana Life Sciences advances foralumab towards commercialization with key manufacturing partnership - Proactive Investors
Tiziana Life Sciences Announces Agreement for Product Development Services with Renaissance Lakewood, LLC - The Manila Times
Tiziana Life Sciences Partners with Renaissance Lakewood to Advance Development of Intranasal Foralumab for Neurodegenerative Diseases - Nasdaq
Tiziana Life Sciences announces dosing of additional patients in MS Expanded Access Program - Proactive Investors UK
Breakthrough MS Treatment Shows Promise: 100% Patient Response Rate in Expanded Trial - StockTitan
Short Interest in Tiziana Life Sciences Ltd (NASDAQ:TLSA) Expands By 128.0% - MarketBeat
3 Promising US Penny Stocks With Market Caps Over $20M - Simply Wall St
Tiziana Life Sciences Announces TV Interview with First Patient Dosed with Moderate Alzheimer’s Disease - GlobeNewswire
Tiziana Life Sciences says foralumab shows promise in Alzheimer’s treatment - Proactive Investors USA
Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Large Drop in Short Interest - MarketBeat
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):